AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3512419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infections due to HSV I
Number of subjects: 60
Study 30573023 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline + naltrexone
Number of subjects: 120
Study 30573023 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline, naltrexone, or varenicline + naltrexone
Number of subjects: 120
Study 30573023 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 30573023 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 120
Study 30573023 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 120
Study 26916095 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of taxane plus bevacizumab (T + BEV)
Number of subjects: 117
Study 26916095 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with exemestane plus bevacizumab (E + BEV)
Number of subjects: 117
Study 23892625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI (n = 180)
Number of subjects: 387
Study 23892625 — intervention group
Group type: COMPARATOR
Intervention: Classical IUI (n = 207)
Number of subjects: 387
Study 23892625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI by senior physician
Number of subjects: 387
Study 23892625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IUI by junior physician
Number of subjects: 387
Study 23892625 — intervention group
Group type: COMPARATOR
Intervention: Classical IUI by senior physician
Number of subjects: 387
Study 24378269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection (GVO)
Number of subjects: 37
Study 24378269 — intervention group
Group type: COMPARATOR
Intervention: Band ligation (GVL)
Number of subjects: 37
Study 24378269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 37
Study 20959009 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific cognitive behaviour group therapy
Number of subjects: 104
Study 20959009 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education programme
Number of subjects: 104
Study 18091014 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training program for the calf muscles (6 weeks)
Number of subjects: 74
Study 18091014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 74
Study 16891014 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (10 microg/kg body weight, for 7 days)
Number of subjects: 20
Study 16891014 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study 12507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline therapy
Number of subjects: 0
Study 12507187 — intervention group
Group type: COMPARATOR
Intervention: High-dose routine therapies
Number of subjects: 0
Study 9718377 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin to achieve and maintain a hematocrit of 42 percent
Number of subjects: 1233
Study 9718377 — intervention group
Group type: COMPARATOR
Intervention: Epoetin to maintain a hematocrit of 30 percent
Number of subjects: 1233
Study 7635132 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vertical vibration at 0.5 Hz
Number of subjects: 8
Study 7635132 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vertical vibration at 4.0 Hz
Number of subjects: 8
Study 7635132 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved visual feedback in task C
Number of subjects: 8
Study 7635132 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm support during vibration at 4.0 Hz
Number of subjects: 8
Study 2692969 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam (0.5 mg twice daily for 5 weeks)
Number of subjects: 30
Study 2692969 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0.5 mg twice daily for 5 weeks)
Number of subjects: 30
Study 922750 — intervention group
Group type: COMPARATOR
Intervention: methyl‐CCNU
Number of subjects: 49
Study 922750 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU plus 5‐FU
Number of subjects: 49
Study 30837253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 80
Study 30837253 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 80
Study 29955136 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI regimen (irinotecan 180 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1-10 of a 14-day cycle)
Number of subjects: 60
Study 29955136 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan monotherapy (irinotecan 180 mg/m2 on day 1 of a 14-day cycle)
Number of subjects: 60
Study 26728475 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilator assist (NAVA)
Number of subjects: 25
Study 26728475 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 25
Study 25112086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needling technique at high stress points
Number of subjects: 60
Study 25112086 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 22810303 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19538002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7000
Study 17998441 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily patient reminder to document seizures
Number of subjects: 91
Study 17998441 — intervention group
Group type: COMPARATOR
Intervention: No reminder (control group)
Number of subjects: 91
Study 15965359 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PCI <2 hours
Number of subjects: 0
Study 15965359 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI (12-72 hours)
Number of subjects: 0
Study 12468958 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release budesonide (4.5 mg)
Number of subjects: 6
Study 12468958 — intervention group
Group type: COMPARATOR
Intervention: Deuterium-labelled standard formulation (4.8 mg)
Number of subjects: 6
Study 12468958 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release budesonide
Number of subjects: 6
Study 12468958 — intervention group
Group type: COMPARATOR
Intervention: Deuterium-labelled standard formulation
Number of subjects: 6
Study 9800927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support by a doula
Number of subjects: 724
Study 9800927 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 724
Study 7710409 — intervention group
Group type: EXPERIMENTAL
Intervention: Akinosi technique
Number of subjects: 250
Study 7710409 — intervention group
Group type: COMPARATOR
Intervention: Conventional mandibular block injection
Number of subjects: 250
Study 2692948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 12
Study 2692948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 334226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 40
Study 334226 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 40
Study 31765997 — intervention group
Group type: EXPERIMENTAL
Intervention: Visibility of time pressure (manipulated condition)
Number of subjects: 39
Study 31765997 — intervention group
Group type: COMPARATOR
Intervention: Visibility of time pressure (visible condition)
Number of subjects: 39
Study 31765997 — intervention group
Group type: EXPERIMENTAL
Intervention: General performance
Number of subjects: 39
Study 31016568 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT1706
Number of subjects: 128
Study 31016568 — intervention group
Group type: COMPARATOR
Intervention: EU‐BEV
Number of subjects: 128
Study 27856497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered ischemia-tolerant MSCs (itMSCs) at a dosage of 1.5×10^6 cells/kg
Number of subjects: 22
Study 27856497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered ischemia-tolerant MSCs (itMSCs)
Number of subjects: 22
Study 27856497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25393934 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 40
Study 25393934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 40
Study 23512917 — intervention group
Group type: EXPERIMENTAL
Intervention: PGX (15 g day(-1) for 14 weeks)
Number of subjects: 64
Study 23512917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22101161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 15 mg
Number of subjects: 22
Study 22101161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 22
Study 22101161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 22
Study 22101161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 22
Study 22101161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19186713 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture twice each day (observation group I)
Number of subjects: 97
Study 19186713 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture once each day (observation group II)
Number of subjects: 97
Study 19186713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received same Chinese drugs and western medicine and electroacupuncture at Jiquan (HT 1), Quchi (LI 11), Hegu (LI 4), Huantiao (GB 30)
Number of subjects: 97
Study 17577686 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid A protein quantification in fat tissue using ELISA with monoclonal antihuman serum amyloid A antibodies.
Number of subjects: 183
Study 17577686 — intervention group
Group type: EXPERIMENTAL
Intervention: Congo red stained slides scored by light microscopy in a semiquantitative way (0 to 4+).
Number of subjects: 183
Study 17577686 — intervention group
Group type: COMPARATOR
Intervention: Comparison of amyloid A protein values between genders and conditions.
Number of subjects: 183
Study 15464679 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide infusion
Number of subjects: 0
Study 11606173 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glycaemia (IFG)
Number of subjects: 657
Study 11606173 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting glucose (NFG)
Number of subjects: 657
Study 9752892 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg)
Number of subjects: 21
Study 9752892 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (5 to 10 mg)
Number of subjects: 21
Study 1901194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundin MCT‐LCT (medium-chain triglycerides)
Number of subjects: 24
Study 1901194 — intervention group
Group type: COMPARATOR
Intervention: Lipofundin S (long-chain triglycerides)
Number of subjects: 24
Study 7042592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1000 mg/day for 5 days)
Number of subjects: 116
Study 7042592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 31419544 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied twice daily for 14 days
Number of subjects: 40
Study 31419544 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 14 days
Number of subjects: 40
Study 31419544 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied open-label to all affected areas for 28 days after initial treatment
Number of subjects: 40
Study 31419544 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole treatment
Number of subjects: 40
Study 26768606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity preoperative resistance training programme (8 weeks, 3 days per week)
Number of subjects: 44
Study 25909892 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedics intervention with frequent patient contact and real-time EMR correspondence
Number of subjects: 0
Study 25163233 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% epidural levobupivacaine
Number of subjects: 81
Study 25163233 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 81
Study 22464008 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily supportive text messages (n=26)
Number of subjects: 54
Study 22464008 — intervention group
Group type: COMPARATOR
Intervention: Fortnightly thank you text message (n=28)
Number of subjects: 54
Study 20372874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (NaCl, 100 mmol/24 h) supplementation during telmisartan treatment
Number of subjects: 0
Study 20372874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus hydrochlorothiazide
Number of subjects: 0
Study 20372874 — intervention group
Group type: COMPARATOR
Intervention: Placebo during telmisartan treatment
Number of subjects: 0
Study 18756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and long-acting nifedipine
Number of subjects: 40
Study 18756750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and moxonidine
Number of subjects: 40
Study 18756750 — intervention group
Group type: COMPARATOR
Intervention: Both combinations
Number of subjects: 40
Study 15934129 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (13 weeks duration)
Number of subjects: 200
Study 15934129 — intervention group
Group type: COMPARATOR
Intervention: PT group
Number of subjects: 200
Study 15934129 — intervention group
Group type: COMPARATOR
Intervention: NP group
Number of subjects: 200
Study 12909492 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (Lng‐IUD)
Number of subjects: 40
Study 12909492 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (surgery only)
Number of subjects: 40
Study 10588467 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (20 g per day for 42 days)
Number of subjects: 19
Study 10588467 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (20 g per day for 42 days)
Number of subjects: 19
Study 9432569 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (100 mg b.i.d.)
Number of subjects: 30
Study 9432569 — intervention group
Group type: COMPARATOR
Intervention: Mesoglycan (50 mg b.i.d.)
Number of subjects: 30
Study 1541143 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyllin) 800 mg taken at night for four weeks
Number of subjects: 12
Study 1541143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4021762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with intensive preoperative irradiation
Number of subjects: 102
Study 4021762 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 102
Study 31439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 75
Study 31439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with leaflets
Number of subjects: 75
Study 31439181 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 75
Study 29935909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Pain Education Video (BP‐DVD)
Number of subjects: 300
Study 29935909 — intervention group
Group type: COMPARATOR
Intervention: General Education DVD on chemotherapy side effects (GE‐DVD)
Number of subjects: 300
Study 29935909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 26613288 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home Men's Program (SAH‐M)
Number of subjects: 135
Study 26613288 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 135
Study 25358552 — intervention group
Group type: EXPERIMENTAL
Intervention: Single set (SS; n=14)
Number of subjects: 27
Study 25358552 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sets (MS; n=13)
Number of subjects: 27
Study 22893943 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional low threshold psychosocial assistance
Number of subjects: 0
Study 22893943 — intervention group
Group type: COMPARATOR
Intervention: Additional psychosocial care
Number of subjects: 0
Study 20124256 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (AChIs)
Number of subjects: 0
Study 20124256 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 20124256 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-approved AD or psychiatric medications
Number of subjects: 0
Study 17646220 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d)
Number of subjects: 133
Study 17646220 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg/d)
Number of subjects: 133
Study 17646220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 15716217 — intervention group
Group type: EXPERIMENTAL
Intervention: ropinirole (1.4mg HS)
Number of subjects: 22
Study 15716217 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 12390903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home
Number of subjects: 399
Study 12390903 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 399
Study 10091815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 6595
Study 7557205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days)
Number of subjects: 172
Study 7557205 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24)
Number of subjects: 172
Study 7557205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lynestrenol 10 mg/d continuously (Group 2, n = 14)
Number of subjects: 172
Study 7557205 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 3, n = 21)
Number of subjects: 172
Study 1916501 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 8
Study 1916501 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 8
Study 1916501 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-study values)
Number of subjects: 8
Study 6259008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplemented diet
Number of subjects: 17
Study 6259008 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 17
Study 31291626 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 23
Study 31291626 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 23
Study 28179586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (Pre-S CRT, weekly cisplatin 30mg/m2)
Number of subjects: 0
Study 26530039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 611
Study 26530039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 611
Study 26530039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 23085976 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dorsiflexion shoes (2°)
Number of subjects: 10
Study 23085976 — intervention group
Group type: COMPARATOR
Intervention: Neutral shoes (0°)
Number of subjects: 10
Study 23085976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tapping-jumping volleyball exercise
Number of subjects: 10
Study 21821506 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) using ropivacaine, ketorolac, and epinephrine
Number of subjects: 50
Study 21821506 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (0.1 mg)
Number of subjects: 50
Study 19663522 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (200 mg/day)
Number of subjects: 52
Study 19663522 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (200 mg/day)
Number of subjects: 52
Study 17893452 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA-V
Number of subjects: 30
Study 17893452 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA-TI
Number of subjects: 30
Study 17893452 — intervention group
Group type: COMPARATOR
Intervention: BM-V
Number of subjects: 30
Study 17893452 — intervention group
Group type: COMPARATOR
Intervention: LG-TI
Number of subjects: 30
Study 15486518 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-150 mg/day
Number of subjects: 24
Study 15486518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11573599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5.5 microg kg(‐1))
Number of subjects: 81
Study 11573599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 9544745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and bile acid sequestrants
Number of subjects: 42
Study 7847600 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nalmefene
Number of subjects: 21
Study 7847600 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nalmefene
Number of subjects: 21
Study 7847600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-group: approximately 0.2 mg/h fentanyl, 2.5 mg/h midazolam, 2 mg/h pancuronium in intermittent doses
Number of subjects: 16
Study 2841885 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-group: about 50 mg/h ketamine and 2.5 mg/h midazolam, 2 mg/h pancuronium
Number of subjects: 16
Study 2841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 2841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-group
Number of subjects: 16
Study 31718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/day)
Number of subjects: 204
Study 31718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 204
Study 31718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg/day) and Rosiglitazone (4 mg/day)
Number of subjects: 204